Synthesis and biological evaluation of potential acetylcholinesterase inhibitors based on a benzoxazine core

With the purpose of expanding the structural variety of chemical compounds available as pharmacological tools for the treatment of Alzheimer's disease, we synthesized and evaluated a novel series of indole‐benzoxazinones (Family I) and benzoxazine‐arylpiperazine derivatives (Family II) for potential human acetylcholinesterase (hAChE) inhibitory properties. The most active compounds 7a and 7d demonstrated effective inhibitory profiles with Ki values of 20.3 ± 0.9 μM and 20.2 ± 0.9 μM, respectively. Kinetic inhibition assays showed non‐competitive inhibition of AChE by the tested compounds. According to our docking studies, the most active compounds from both series (Families I and II) showed a binding mode similar to donepezil and interact with the same residues.

[1]  Stanislav Kozlov,et al.  Alzheimer’s disease: as it was in the beginning , 2017, Reviews in the neurosciences.

[2]  A. Anand,et al.  The present and future of pharmacotherapy of Alzheimer’s disease: A comprehensive review , 2017, European journal of pharmacology.

[3]  M. Tavares,et al.  Synthesis, Molecular Modeling, and Evaluation of Novel Sulfonylhydrazones as Acetylcholinesterase Inhibitors for Alzheimer's Disease , 2017, Archiv der Pharmazie.

[4]  S. Waldvogel,et al.  New Approach to 1,4-Benzoxazin-3-ones by Electrochemical C-H Amination. , 2017, Chemistry.

[5]  L. Piemontese,et al.  Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer’s disease therapy , 2017, Neural regeneration research.

[6]  R. Fremeau,et al.  The discovery of benzoxazine sulfonamide inhibitors of NaV1.7: Tools that bridge efficacy and target engagement. , 2017, Bioorganic & medicinal chemistry letters.

[7]  Simone Brogi,et al.  Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease , 2017, Progress in Neurobiology.

[8]  A. Shafiee,et al.  Synthesis and anticholinesterase activity of coumarin-3-carboxamides bearing tryptamine moiety. , 2016, European journal of medicinal chemistry.

[9]  Sarah A. Chau,et al.  Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments. , 2016, Current Alzheimer research.

[10]  Sunil K. Sharma,et al.  Design and Synthesis of Novel Triazolyl Benzoxazine Derivatives and Evaluation of Their Antiproliferative and Antibacterial Activity , 2016 .

[11]  L. Qiu,et al.  Synthesis and characterization of one novel second-order nonlinear optical chromophore based on new benzoxazin donor , 2016 .

[12]  Jan Korabecny,et al.  Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats—Is there a potential for Alzheimer’s disease treatment? , 2016, Neuroscience Letters.

[13]  Y. K. Yoon,et al.  Structural Modifications of Benzimidazoles via Multi‐Step Synthesis and Their Impact on Sirtuin‐Inhibitory Activity , 2016, Archiv der Pharmazie.

[14]  A. Shafiee,et al.  Synthesis and Evaluation of Chroman‐4‐One Linked to N‐Benzyl Pyridinium Derivatives as New Acetylcholinesterase Inhibitors , 2015, Archiv der Pharmazie.

[15]  A. Shafiee,et al.  9H‐Carbazole Derivatives Containing the N‐Benzyl‐1,2,3‐triazole Moiety as New Acetylcholinesterase Inhibitors , 2015, Archiv der Pharmazie.

[16]  M. Salmona,et al.  Synthesis and binding properties of new long-chain 4-substituted piperazine derivatives as 5-HT₁A and 5-HT₇ receptor ligands. , 2015, Bioorganic & medicinal chemistry letters.

[17]  Gonzalo Recabarren‐Gajardo,et al.  Synthesis and Biological Screening of Novel Indolalkyl Arenes Targeting the Serotonine Transporter , 2014, Archiv der Pharmazie.

[18]  R. Araya-Maturana,et al.  Synthesis, docking and pharmacological evaluation of novel homo- and hetero-bis 3-piperazinylpropylindole derivatives at SERT and 5-HT1A receptor. , 2013, Bioorganic & medicinal chemistry.

[19]  Sivakumar Prasanth Kumar,et al.  Design, Synthesis, Biological Evaluation, and Molecular Modeling of Coumarin–Piperazine Derivatives as Acetylcholinesterase Inhibitors , 2013, Archiv der Pharmazie.

[20]  P. Dobes,et al.  Caffeine Inhibits Acetylcholinesterase, But Not Butyrylcholinesterase , 2013, International journal of molecular sciences.

[21]  M. Rudolph,et al.  Structures of human acetylcholinesterase in complex with pharmacologically important ligands. , 2012, Journal of medicinal chemistry.

[22]  R. Araya-Maturana,et al.  Synthesis, 5-hydroxytryptamine1A receptor affinity and docking studies of 3-[3-(4-aryl-1-piperazinyl)-propyl]-1H-indole derivatives. , 2012, Chemical & pharmaceutical bulletin.

[23]  M. Kamel,et al.  Synthesis of New Indole Derivatives Structurally Related to Donepezil and Their Biological Evaluation as Acetylcholinesterase Inhibitors , 2012, Molecules.

[24]  B. R. Raju,et al.  A simple and facile route for the synthesis of 2H-1,4-benzoxazin-3-(4H)-ones via reductive cyclization of 2-(2-nitrophenoxy)acetonitrile adducts in the presence of Fe/acetic acid , 2011 .

[25]  S. D’Mello,et al.  Synthesis of 2-Benzylidene and 2-Hetarylmethyl Derivatives of 2H-1,4-Benzoxazin-3-(4H)-ones as Neuroprotecting Agents , 2010 .

[26]  S. Chandrasekhar,et al.  An efficient synthesis of 2H-1,4-benzoxazin-3(4H)-ones via Smiles rearrangement , 2008 .

[27]  S. Moore,et al.  The peripheral anionic site of acetylcholinesterase: structure, functions and potential role in rational drug design. , 2006, Current pharmaceutical design.

[28]  J. Ilaš,et al.  Recent advances in the synthesis of 2H-1,4-benzoxazin-3-(4H)-ones and 3,4-dihydro-2H-1,4-benzoxazines , 2005 .

[29]  Anne W. Schmidt,et al.  Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides. , 2004, Journal of medicinal chemistry.

[30]  S. Anzali,et al.  Synthesis and Structure−Activity Relationship in a Class of Indolebutylpiperazines as Dual 5-HT1A Receptor Agonists and Serotonin Reuptake Inhibitors , 2004 .

[31]  Zoran Radić,et al.  Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site , 2003, The EMBO journal.

[32]  J. Sussman,et al.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. , 1999, Structure.

[33]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[34]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.